Thank today. key you, advancing significant were joining year. Nicole and our thanks to for objectives everyone milestones In for us cytisinicline crucial meeting achieved XXXX, to the and we that
first to on smoking including become We for cytisinicline critical the new belief positive are cessation, the dependence. which successfully standard executed regimen yielded treating new our to have our and dosage outcome proud confirmed X and nicotine This Phase has for safety highly that results. trial of numerous our efficacy activities, the gold completion potential
who funding in to expectations cessation to which and vaping trial, initiate the the study first vaping. enthusiasm our our sites with participants grant due quit at enrollment exceeded great early completing secured to wanted We
a property concluding intellectual our XX strengthened also We XX the total year granted patents, expirations position, extending XXXX. with including of pending and patents out until
to activities completion speak requirements. upcoming meet in productive cytisinicline only partners. full-time commercial capital of API numerous ensure take to health. of a the of facility, greatly new great impact with Achieve expected roles potential commitment the pride employees. meaningful make XXXX, expanding advancing team critical with team the engaged of a accomplishments public Along manufacturing we We XX various their our our And development for to expertise and These the in completing build-out milestones. these we global capacity Sopharma, our secured discussions with to completed partner, we to strategic our finally, in In also
significant XXXX. We are the receive the even now in progress we our support grateful efforts promises ahead, year We look be to external to continue and for we And for their exciting. more to made which from stakeholders. forward
focus our XXXX. to milestones for and priorities that, With upcoming turns the
reporting explore ORCA-VX, X two initiating from we nicotine grant ORCA-X, trial results, will our ORCA-VX, X ORCA-VX clinical through had have our cessation, line Phase for Beginning top Phase followed users reasons. XXX nicotine first, vaping in funded trial smoking two with Next NIH, trials second sites, months enrollment, approximately for X trial randomized cessation. NIDA quarter, adult support of e-cigarettes for across this partially population aims to and of ORCA-VX by X
there believe and second, be in we that a cytisinicline and it cessation receptors vaping is its in mechanism in nicotine area. growing cessation the in effective brain; of as need unmet action First, smoking the on will as significant this given is
Our demonstrate smokers’ of to clinical to their We broadly, trial chances vaping. including believe placebo. effect applicable that cytisinicline significantly improves nicotine nicotine other as findings more thus to far overcoming be administration modalities this compared will addiction of
using a – data by who has adolescents among that in students profile, e-cigarettes. be school X.X for a very combustible to and e-cigarettes CDC reported are in cigarettes important the more likely well-tolerated adolescents has particularly and approximately treatment in the concern. future. is November middle cytisinicline which Additionally, been in try that school According growing treating the high use e-cigarettes, also million particular, side outcomes. we successful have XXXX, Xx demonstrated of It use ultimately to effect The compliance may released were U.S.
estimated X the which are adult an of users U.S. alone. of there on Our vaping study, ORCA-VX, in million focuses e-cigarettes,
make adult research, presenting treatment of and in a seeking showing a significant in ORCA-VX potential cytisinicline to on While and the effects learn health. important will trials, last impact consideration may it pediatric lot the stopping clearly issues opportunity indication, cytisinicline currently future not the of a trial. primary abstinence the treatment. public vapors from the during be of verified around be a for nicotine trial understanding results we to for this The are e-cigarette will is one, a study Similar population This weeks we continuous biochemically smoking dependence. another is cessation X endpoint the younger
metabolite verification completed of dose in of earlier trials, received is cotinine last the subject these subject visit is which month. and in based was this the on February ORCA-VX biochemical their nicotine. However, systemic final levels, The a last
milligrams we line quarter, next smoking stated, our the locations either the for in U.S. clinical second Phase tolerability for the trial previous XX are cytisinicline cytisinicline second weeks cessation. The subjects efficacy, of times from top X mirrors our quarter. study As randomized trial to on last compared X X results XX our across evaluating ORCA-X dosed. trial results We expected in ORCA-X had XXX X ORCA-X X announced report with safety in and January daily that dosed track previously Also subject Phase been in placebo. or of ORCA-X
determined the continuous XX will receiving both placebo. X or ORCA-X, a of of standard the show treatment be either arm, during Each Subjects to compared be Identical behavioral for successful trial. post treatment of compared duration are and will the if to to independently cytisinicline randomization primary being placebo last biochemically is the be statistical support to the arm endpoint arms and the benefit trial monitored treatment. abstinence the weeks verified weeks through
placebo publication. trial aims have received results benefit a to observed the in XX Similar ORCA-X to power which with weeks. for compared replicate to to The continue to trial, continued was been approximately comparison ORCA-X XX% abstinence long-term ORCA-X well ORCA-X, submitted at designed demonstrate follow-up to the the positive be at able be and
was age, gender, quit placebo. observed successful of the additional regardless month, Research for highlighted previous from rates on at this ORCA-X and received who Meeting. history, Rigotti or cytisinicline abstinence Dr. by presented smokers treatments. prior compared smoking Annual Nancy smokers observed benefit presentation Earlier who Tobacco analyses received subgroups attempts Her by cytisinicline The of Nicotine abstinence were Society to the in
measured and provide Prevalence additional received abstinence multiple when the details data at we who time demonstrated throughout of trial. Subjects all under able also at points was compared on time the the placebo to consistently Congress. throughout abstinence Medical publication, of behavior with consistent to cytisinicline not Due points are higher XX-week insights study. specific the presented rates for the study provide being more review outside
continue However, quit journey. affirm are who demographic the of our potential in and cytisinicline of a various stages both their for smokers X belief wide these of of XX-week dosing data to at
our sections member we the beginning readouts, fully significant non-clinical, engaged possesses and select Moving in to particularly filing team draft recently while anticipated hand, a team final full-time we Application, NDA is U.S. this trial the regulatory process, we with NDA, Drug filings. the experience With who also for preparations in await organize clinical are hired have data lead highly in To NDA New robust a of of beyond amount or data.
financial At this to to over time, our I’d like turn update. call Jerry the for
